New Collaboration to Evaluate Lower-Dose Gene Therapy Conditioning for Sickle Cell Disease

Jasper Therapeutics and Aruvant Sciences are studying the use of JSP191 used with ARU-1801 in patients with sickle cell disease.

Car T-Cell Therapy: The Future of Multiple Myeloma Treatment?

C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in myltiple myeloma.

The Potential of CAR T-Cell Therapy for Multiple Myeloma

James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.

CAR T-Cell Therapy for Early-Relapsed Multiple Myeloma

Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.

Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Broadening Gene Therapy's Reach With Novel Capsids

LogicBio's Mariana Nacht, PhD, shares details of the company's novel capsid discovery platform and gene editing technology.